sacubitril/valsartan

Generic Name: sacubitril/valsartan

Brand Name: Entresto

Manufacturer: Novartis Pharma Inc.

Therapeutic Area: Heart failure, NYHA Class II or III

Indications: Entresto is indicated for the treatment of heart failure with reduced ejection fraction (HFrEF) in patients with NYHA Class II or III, to reduce the incidence of cardiovascular death and heart failure hospitalisation. Entresto should be administered in combination with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB). Entresto should be initiated, and up-titration conducted, by a physician experienced with the treatment of heart failure.

Manufacturer Requested Reimbursement Criteria¹: Addition to the current criteria: Initiation of sacubitril/valsartan may be considered in patients stabilized from a heart failure hospitalization without prior exposure to angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB).

Submission Type: Resubmission

NOC Status at Filing: Post NOC

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule B

1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.